DRIVING INNOVATION AND SAFETY:
THE CRITICAL ROLE OF EUROPEAN PHARMACEUTICAL EXCIPIENTS

What are pharmaceutical excipients?

EU-manufactured excipients are essential to the safety, performance and scalability of modern medical products. Strengthening the EU's excipients industry is critical to sustaining pharmaceutical innovation, supply security and global competitiveness. They:

Ensure **stability and integrity of APIs** throughout shelf life

Control **delivery and release** to achieve the desired therapeutic effect

Enhance **bioavailability of complex and poorly soluble molecules**

Improve **patient usability and adherence**

Enable **robust, cost-effective and scalable manufacturing**

Alongside APIs, pharmaceutical excipients are essential to medicinal products manufacturing—supporting innovation, supply resilience, and Europe's strategic autonomy while ensuring medicines are stable, effective, and safe for patients.



In every medicinal product, the API is the payload, delivering the therapeutic effect that treats, prevents or manages disease. Excipients are the propulsion system, enabling medicines to reach their destination safely and effectively.

Pharmaceutical excipients at a glance

95%
Up to 95% of a medicine's mass is excipients

€10Bn[1]
Global market size

38%
With around 38% of global market share, Europe is the largest regional market for pharmaceutical excipients[2]



Diverse origins
synthetic, bio-based and mineral

[1] External Market Report - Pharmaceutical Process Materials Global Market Size and Dynamics - 2024 - Oliver Wyman
[2] Pharma Excipients Market to Project USD 16.12 Bn by 2035

Excipients power innovation in modern medicines

Enable
delivery of complex APIs

Unlock
advanced drug delivery systems



Offer
patient -friendly solutions

Innovative excipients enable more patient-friendly options, improving access and adherence. Example: they can allow biologics to be taken orally instead of by injection, maintaining the same therapy with greater convenience for patients.

EU-manufactured excipients

A global benchmark for sustainability, quality and supply security

Rigorous EU regulatory and quality standards, including broadly applied voluntary schemes[3]

Leadership in bio-based and sustainable materials

Fully transparent and traceable supply chains

Structurally lower carbon footprint

Strong social and governance standards

[3] Excipient are subject to the scrutiny of multisector EU regulatory bodies. Given the diverse origin of excipients, IPEC & EXCiPACT define guides and standards to define the appropriate GMP, GDP & Quality Standards, with high uptake of EXCiPACT Certifications among European pharmaceutical excipients manufacturers.

The EU pharmaceutical excipients industry

With a global market size of approximately €10 billion annually, excipients underpin the development, manufacturing and supply of modern medicines.

As the second largest excipients market globally, Europe plays a central role in:

Ensuring **secure and reliable supply chains**

Supporting **innovation in advanced therapies** and complex formulations

Maintaining **high quality** and regulatory standards

However, this position is not guaranteed.
Increasing global competition, cost pressures and shifting supply chains risk eroding Europe's leadership.
Sustained investment and policy support are essential to:



Ensure long-term patient access to **safe and effective medicines**

Safeguard Europe's strategic autonomy in medicines

Maintain a **competitive and innovative** industrial base

efcg EUROPEAN FINE CHEMICALS GROUP www.efcg.cefic.org

www.ipec-europe.org IPEC EUROPE